PlumX Metrics
Embed PlumX Metrics

Interleukin-31 as a Clinical Target for Pruritus Treatment

Frontiers in Medicine, ISSN: 2296-858X, Vol: 8, Page: 638325
2021
  • 70
    Citations
  • 0
    Usage
  • 90
    Captures
  • 14
    Mentions
  • 36
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    70
  • Captures
    90
  • Mentions
    14
    • News Mentions
      14
      • News
        14
  • Social Media
    36
    • Shares, Likes & Comments
      36
      • Facebook
        36

Most Recent News

An itching paradox – a molecule that triggers the urge to scratch also turns down inflammation in the skin

Itching can be uncomfortable, but it’s a normal part of your skin’s immune response to external threats. When you’re itching from an encounter with poison

Review Description

In recent years, the published literature has suggested the key involvement of the cytokine interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have become potential therapeutic targets for a range of pruritic diseases. Elevated levels of IL-31 or its receptor have been reported in the tissue or serum of patients with pruritic skin diseases, such as atopic dermatitis, prurigo nodularis, and psoriasis. Pruritus places a heavy burden on patients, and can have a negative impact on daily life, sleep, and mental health. Since current anti-pruritic treatments are often ineffective, affected patients are in urgent need of new therapies. As a result, drug development targeting the IL-31 pathway is evolving rapidly. To date, only nemolizumab, a humanized monoclonal antibody targeting the IL-31 receptor, has successfully completed late-stage clinical studies. This article will highlight our current clinical understanding of the role of IL-31 in pruritic disease, and explore recent progress in drug development as well as the anticipated future advances in this field.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know